000			01925 a2200565 4500
005			20250515110531.0
264		0	_c20080219
008			200802s 0 0 eng d
022			_a1533-4406
024	7		_a10.1056/NEJMoa0706383 _2doi
040			_aNLM _beng _cNLM
100	1		_aHauser, Stephen L
245	0	0	_aB-cell depletion with rituximab in relapsing-remitting multiple sclerosis. _h[electronic resource]
260			_bThe New England journal of medicine _cFeb 2008
300			_a676-88 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntigens, CD20
650	0	4	_aB-Lymphocytes _xdrug effects
650	0	4	_aBrain _xpathology
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aGadolinium
650	0	4	_aHumans
650	0	4	_aImmunoglobulins _xblood
650	0	4	_aImmunologic Factors _xadverse effects
650	0	4	_aInfusions, Intravenous
650	0	4	_aMagnetic Resonance Imaging
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy
650	0	4	_aRemission Induction
650	0	4	_aRituximab
700	1		_aWaubant, Emmanuelle
700	1		_aArnold, Douglas L
700	1		_aVollmer, Timothy
700	1		_aAntel, Jack
700	1		_aFox, Robert J
700	1		_aBar-Or, Amit
700	1		_aPanzara, Michael
700	1		_aSarkar, Neena
700	1		_aAgarwal, Sunil
700	1		_aLanger-Gould, Annette
700	1		_aSmith, Craig H
773	0		_tThe New England journal of medicine _gvol. 358 _gno. 7 _gp. 676-88
856	4	0	_uhttps://doi.org/10.1056/NEJMoa0706383 _zAvailable from publisher's website
999			_c17777769 _d17777769